An FDA sign - health policy coverage from Thrive Rx

What the FDA's peptide reversal means for Australia

The FDA is reversing restrictions on peptide compounding. Here's what changed in the US, why Australia's TGA is taking the opposite approach, and what it means for you.

Thrive Rx Digital Health Team

The FDA's decision to revisit restrictions on peptide compounding has generated headlines worldwide. For Australians following the health optimisation space, the natural question is whether this changes anything here.

The short answer: not directly. Australia's Therapeutic Goods Administration (TGA) operates independently of the FDA, and the two regulators are currently moving in opposite directions. But the longer answer is worth understanding, because the regulatory environment around peptides is shifting in ways that affect how Australians access clinical care.

What happened in the US

In September 2023, the FDA placed 19 peptides on its Category 2 restricted list, preventing US compounding pharmacies from preparing them. The agency cited concerns about immunogenicity risk, peptide-related impurities, and a lack of controlled human clinical trial data for most of the substances involved.

The restrictions prompted legal challenges from compounding pharmacies and medical groups, who argued the FDA had overstepped its authority and violated proper administrative procedure. In September 2024, a legal settlement resulted in five peptides being removed from the restricted list and referred for formal scientific review.

The bigger shift came in February 2026, when US Health Secretary Robert F. Kennedy Jr. announced intent to reverse restrictions on a subset of the 19 peptides. On 15 April 2026, the FDA formally scheduled a meeting of its Pharmacy Compounding Advisory Committee (PCAC) for 23-24 July 2026, and the July 2026 PCAC agenda specifically lists seven peptides for review, including BPC-157, TB-500, KPV, and MOTS-c. None of these compounds are TGA-approved for use in Australia, and an FDA reclassification would not change their Australian regulatory status.

Two points worth noting here. First, reclassification is not the same as FDA approval. If these peptides are moved back to Category 1, they can be legally compounded under a prescription, but they remain unapproved drugs that have not undergone the standard clinical trial process. Second, the announcement of intent is not a regulatory action. The formal review process is still underway, and the PCAC's recommendations are advisory, not binding.

Where Australia stands

While the US moves toward loosening access, the TGA is moving in the other direction.

On 14 April 2026, the TGA issued a safety alert warning of a rise in the import, supply, compounding, and advertising of unapproved peptide products. The alert noted that these products have not been assessed by the TGA for safety, quality or effectiveness, and flagged reports of severe allergic reactions leading to hospitalisation, inflammation, palpitations, and musculoskeletal injuries.

ABC News reported that the Australian Medical Association's public health committee chair called for the TGA to be "more aggressive" in enforcement. The TGA itself stated it is "actively monitoring this issue from both safety and law enforcement perspectives," with penalties for serious breaches reaching $16.5 million in fines or seven years' imprisonment.

Australia's regulatory architecture also differs from the US in fundamental ways. The US has a two-tier compounding system (503A pharmacies for patient-specific prescriptions and 503B outsourcing facilities for larger-scale production), with a specific "bulks list" that determines which ingredients compounders can use. Australia has no equivalent structure. Under the Therapeutic Goods Act 1989, compounding is only permitted where a product is prepared for an individual patient based on a valid prescription, and where no suitable approved alternative exists.

Why the regulatory difference matters

An FDA reclassification has no direct legal effect in Australia. The TGA's scheduling decisions, the Australian Register of Therapeutic Goods, and the Therapeutic Goods Act are entirely separate frameworks.

What an FDA reversal does affect is demand. RACGP NSW/ACT Deputy Chair Dr James Kelly told newsGP that peptide interest is increasingly driven by social media, noting he is hearing about it more and more from patients who have seen something on TikTok or been offered a product through a gym or fitness group. US regulatory changes amplify that visibility, which flows into Australian social media feeds and creates pressure on both consumers and practitioners.

This is where the grey-market risk becomes real. When demand rises and regulated access pathways are limited, people turn to unregulated sources. Imported peptide products purchased online may carry inaccurate labelling, unknown purity, contamination risks, and no clinical oversight. A ProPublica investigation published in April 2026 found that Chinese peptide imports to the US doubled to $328 million over the first three quarters of 2025, with online peptide advertising up 678% since 2022. Australia is not immune to these same market dynamics.

Dr Kelly put it plainly: "Regulation and evidence are key, and it is the consumer, not the seller, who is always the one carrying the risk."

What this means if you're considering peptide therapy

The regulatory environment is changing, but the core principle in Australia remains the same: clinical assessment first, always.

Australia does have regulated pathways for accessing unregistered medicines, and each requires a clinical assessment as the entry point - ongoing oversight and a valid prescription, not an online purchase.

At Thrive Rx, all clinical decisions are made by Ahpra-registered clinicians who review your pathology, medical history, and health goals before recommending any protocol. If peptide therapy is clinically appropriate for you, your clinician can determine the right approach within the existing regulatory framework. That process starts with comprehensive pathology and a clinical assessment, not a social media post.

If you're interested in understanding what your biomarkers reveal about your health, start your assessment today.

Disclaimer
All information is general and not intended as a substitute for professional advice.

References

Longevity and regenerative medicine ›